Rocket Pharmaceuticals, Inc.
NASDAQ Global MarketTotal Valuation
Rocket Pharmaceuticals, Inc. carries a market capitalization of 293.73M, placing it among publicly traded companies globally. Its enterprise value stands at 115.68M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 293.73M |
| Enterprise Value | 115.68M |
Share Statistics
Rocket Pharmaceuticals, Inc. currently has 109.54M shares outstanding.
| Shares Outstanding | 109.54M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 1.02 |
| P/TBV Ratio | 1.23 |
| P/FCF Ratio | -2.26 |
| P/OCF Ratio | -2.25 |
Financial Position
Rocket Pharmaceuticals, Inc. maintains a current ratio of 9.24, meaning it holds 9.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.72, indicating elevated leverage, while an interest coverage ratio of -96.29 demonstrates limited ability to service its debt obligations.
| Current Ratio | 9.24 |
| Quick Ratio | 9.06 |
| Debt / Equity | 6.72 |
| Debt / EBITDA | -0.14 |
| Interest Coverage | -96.29 |
Financial Efficiency
| Return on Equity (ROE) | -4.77 |
| Return on Assets (ROA) | -4.09 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -3.85 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, Rocket Pharmaceuticals, Inc. has paid 8.62M in income taxes, reflecting an effective tax rate of 6.54.
| Income Tax | 8.62M |
| Effective Tax Rate | 6.54 |
Stock Price Statistics
Rocket Pharmaceuticals, Inc.'s stock has declined approximately -18.9759% over the past 52 weeks. The 50-day moving average sits at 3.47, while the 200-day moving average is 3.59.
| Beta (5Y) | N/A |
| 52-Week Price Change | -18.9759% |
| 50-Day Moving Average | 3.47 |
| 200-Day Moving Average | 3.59 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -182.18M, while operating income came in at -191.88M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -191.88M |
| Pretax Income | -8.63M |
| Net Income | -17.25M |
| EBITDA | -182.18M |
| EBIT | -191.88M |
| Earnings Per Share (EPS) | -0.15 |
Balance Sheet
Rocket Pharmaceuticals, Inc. holds 283.75M in cash and equivalents against 24.80M in total debt, resulting in a net debt position of -224.51M. Total book value stands at 368.83M, with working capital of 258.23M providing operational flexibility.
| Cash & Cash Equivalents | 283.75M |
| Total Debt | 24.80M |
| Net Debt | -224.51M |
| Equity (Book Value) | 368.83M |
| Book Value Per Share | 3.37 |
| Working Capital | 258.23M |
Cash Flow
Rocket Pharmaceuticals, Inc. produced -170.27M in operating cash flow over the past twelve months. After subtracting -127,000.00 in capital expenditures, free cash flow totaled -170.39M - equivalent to -1.52 per share.
| Operating Cash Flow | -170.27M |
| Capital Expenditures | -127,000.00 |
| Free Cash Flow | -170.39M |
| FCF Per Share | -1.52 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.02 |
| FCF Yield | -44.22 |
Stock Splits
Rocket Pharmaceuticals, Inc.'s most recent stock split took place on January 5, 2018 with a 4:1 split ratio.
| Last Split Date | 1/5/2018 |
| Split Ratio | 4:1 |
Scores
Rocket Pharmaceuticals, Inc. posts an Altman Z-Score of -2.09, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -2.09 |